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De Rosa et al. considered clinical scores, biomarkers and their combi-nation as useful aids for an early antifungal treatment and advocated the adoption of de-escalation therapy in an antifungal stewardship 
approach as a possible key for a better management of these patients. Authors 
considered the high burden of invasive fungal infections in terms of patient 
outcomes and costs and focused on current strategies for their optimization. 
The fact that many non-neutropenic, critically ill patients with invasive fun-
gal infection die despite being treated with effective antifungal agents may 
provide interesting insights on additional, patient-related conditions that 
may play a role for final outcome.
The role of immunity in septic patients has been studied for many years. 
Nowadays, we have evidence on the role of impaired immunological re-
sponse in not-formally considered immunosuppressed patients (e.g. 
non-transplant recipients, non-neutropenic patients), namely decreased 
cytokines production, increased number of T regulatory cells and of 
pro-apoptotic signal (programmed cell death 1receptor, PD-1  and ligand, 
PD-L1) (1-3). Moreover, it should be also considered that nosocomial 
sepsis is commonly caused by weakly virulent pathogens (Acinetobacter 
spp., Pseudomonas spp., Stenotrophomonas spp., and Candida spp.) and 
septic patients show a high incidence (25–35%) of reactivation of virus-
es  (cytomegalovirus, herpes simplex virus) which are hold in abeyance 
by an effective immunological response. Recently, Spec et al. (4) (from 
Hotchkiss’ group) published an observational study investigating the im-
munophenotype of non-neutropenic patients with candidemia compared 
to critically ill, non-septic controls. Both CD4 and CD8 T cells of pa-
tients with candidemia expressed markers of cell exhaustion (PD1 and 
PD-L1) and a down regulation of positive co-stimulatory molecules (4). 
These preliminary data may represent the missing brick contributing to 
explain the paradox between the reduction of the incidence of invasive 
fungal infections and the lack of survival benefit after untargeted antifun-
gals administration (5, 6). We may speculate that the impaired immune 
response may have a causative role on the lack of benefit of highly effective 
antifungals or it may rather represent a marker of severe underlying disease. 
If confirmed, the identification of immunologic exhaustion as a hallmark 
of patients with a higher risk of invasive fungal infections may be consid-
ered for better selection of patients in future trials of antifungal treatments. 
Moreover, it may open the door to a novel therapeutic approach to fungal 
sepsis based on immunomodulatory therapies. To date, research efforts on 
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antifungal sepsis focused on strategies for early administration of 
antifungals given the reported high attributable morbidity and 
mortality of invasive fungal infections. This has led to develop-
ment of clinical scores, identification of fungal biomarkers and 
untargeted approaches for invasive fungal infection prevention 
(7, 8). Evidence from randomized trials did not demonstrate, to 
date, an advantage of untargeted administration of antifungals in 
non-neutropenic critically ill patients (9, 10). In this sense, anti-
fungal drug administration has been included among the growing 
list of “the less is better” interventions in ICU.  Despite this lack of 
evidence, up to 8% of ICU patients without proven Candida spp. 
infection receive an antifungal drug and a significant proportion 
of patients who received an antifungal will not develop a fungal 
infection (11). This has led to antifungal exposure with increased 
risk of emergence of resistance, drug-related adverse events and 
costs (12). Furthermore, the issue of immunological impairment 
should perhaps be clinically evaluated by epidemiological and mi-
crobiological perspectives for Enteropathogenetic syndromes and 
for the possibilities of invasive infections included in the acronym 
“CCC”: Candida, Carbapanemases-producing bacteria (such as 
Klebsiella pneumoniae) and C. difficile colitis (13-15).
After 30 years of research, there are still some unsolved questions 
about antifungal treatment in non neutropenic critically ill patients 
remains:
1) Should we go on with early administration of antifungals to crit-
ically ill patients despite the evidence not supporting their use to 
improve survival? 
2) How to better select patients who may the most from antifungal 
administration? 
3) Will immunomodulatory therapies be a feasible, valuable option 
for patients with fungal sepsis or at risk of developing it? 
To date, international guidelines and a stewardship approach are 
the only available answers.
References
1. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veer-
donk FL. Immune defence against Candida fungal infections. Nat 
Rev Immunol 2015; 15: 630-42. [CrossRef ]
2. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death 
and inflammation in sepsis. Nat Rev Immunol 2006; 6: 813-22. 
[CrossRef ]
3. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coo-
persmith CM, et al. Characterization and modulation of the immu-
nosuppressive phase of sepsis. Infect Immun 2010; 78: 1582-92. 
[CrossRef ]
4. Spec A, Shindo Y, Burnham CA, Wilson S, Ablordeppey EA, Be-
iter ER, et al. T cells from patients with Candida sepsis display 
a suppressive immunophenotype. Critical Care 2015; 20: 1-9. 
[CrossRef ]
5. Cortegiani A, Russotto V, Raineri SM, Giarratano A. The paradox of 
the evidence about invasive fungal infection prevention. Critical Care 
2016; 20: 114. [CrossRef ]
6. Russotto V, Cortegiani A, Raineri SM, Giarratano A. From bedside to 
bench: the missing brick for patients with fungal sepsis. Critical Care 
2016; 20: 191. [CrossRef ]
7. Cortegiani A, Russotto V, Raineri SM, Giarratano A. Antifungal pro-
phylaxis: update on an old strategy. Eur J Clin Microbiol Infect Dis 
2016; 35: 1719-20. [CrossRef ]
8. Cortegiani A, Russotto V, Raineri SM, Giarratano A. Is it time to 
combine untargeted antifungal strategies to reach the goal of ‘early’ 
effective treatment? Critical Care 2016; 20: 241. [CrossRef ]
9. Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Rain-
eri SM, et al. Antifungal agents for preventing fungal infections in 
non-neutropenic critically ill patients. Cochrane Database Syst Rev 
2016: CD004920. [CrossRef ]
10. Cortegiani A, Russotto V, Raineri SM, Gregoretti G, Giarratano A. 
Should we continue to use prediction tools to identify patients at risk 
of Candida spp. infection? If yes, why? Critical Care 2016; 20: 351. 
[CrossRef ]
11. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais 
A, et al. Systemic antifungal therapy in critically ill patients with-
out invasive fungal infection. Critical Care Med 2012; 40: 813-22. 
[CrossRef ]
12. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Cat-
ania J, Booker R, et al. Increasing echinocandin resistance in Candida 
glabrata: clinical failure correlates with presence of FKS mutations 
and elevated minimum inhibitory concentrations. Clin Infect Dis 
2013; 56: 1724-32. [CrossRef ]
13. De Rosa FG, Corcione S, Raviolo S, Montrucchio C, Aldieri C, 
Pagani N, et al. Candidemia, and infections by Clostridium diffi-
cile and carbapenemase-producing Enterobacteriaceae: new entero-
pathogenetic opportunistic syndromes? Infez Med 2015; 23: 105-
16.
14. De Rosa FG, Corcione S, Cavallo R, Di Perri G, Bassetti M. Critical 
issues for Klebsiella pneumoniae KPC-carbapenemase producing K. 
pneumoniae infections: a critical agenda. Future Microbiol 2015; 10: 
283-94. [CrossRef ]
15. De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE 
to ESCAPE, From KPC to CCC. Clin Infect Dis 2015; 60: 
1289-90.[CrossRef ]
Antifungal Treatment    CORTEGIANI vs. DE ROSA Second Round
DEBATE
286
